Five years ago, the Food and Drug Administration launched a new program to speed the development and review of cutting-edge and potentially lifesaving medical devices, all in the name of getting them to patients faster. But a STAT investigation has found that while the Breakthrough Devices Program has delivered big benefits to companies making devices, its value to patients is still far from clear. Read more. Check out last month's top stories. If you like what you see, join our STAT+ community today — and enjoy 25% off your first year. More of our top stories: Subscribe now to enjoy 25% off your first year. SUBSCRIBE | |
No comments